Study of Integrity of Down Inhibitor Bundle at Patients Suffering of Neuropathic Pain (PhyDoNe)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by University Hospital, Clermont-Ferrand.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Grünenthal GmbH
Information provided by:
University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier:
NCT01053845
First received: January 19, 2010
Last updated: January 18, 2011
Last verified: January 2011
  Purpose

Several studies showed that activity of down inhibitor bundle is weakened in different painful pathologies as the fibromyalgy or the trigeminal nevralgy.

The purpose of the protocol is to study the working of down inhibitor bundle at patients suffering of neuropathic pain.


Condition Intervention Phase
Healthy Volunteers
Patients Suffering of Peripheral Neuropathic Pain
Other: Neuropathic pain
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Study of Integrity of Down Inhibitor Bundle at Patients Suffering of Neuropathic Pain

Further study details as provided by University Hospital, Clermont-Ferrand:

Primary Outcome Measures:
  • Comparison of the amplitude of N2P2 waves between healthy volunteers and patients suffering of peripheral neuropathic pain. [ Designated as safety issue: Yes ]

Estimated Enrollment: 20
Study Start Date: April 2010
Estimated Study Completion Date: February 2012
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Neuropathic pain
    to study the working of down inhibitor bundle at patients suffering of neuropathic pain
Detailed Description:

Prospective study with comparison groups

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • neuropathic patients group

    • Patient suffering of peripheral neuropathic pain
    • 18 years old women or men at least

Exclusion Criteria:

  • • Healthy volunteers

    • 18 years old women or men at least
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01053845

Contacts
Contact: Patrick Lacarin placarin@chu-clermontferrand.fr

Locations
France
Chu Clermont-Ferrand Recruiting
Clermont-Ferrand, France, 63003
Contact: Patrick LACARIN    04 73 75 11 95    placarin@chu-clermontferrand.fr   
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Grünenthal GmbH
Investigators
Principal Investigator: Gisèle Pickering, Dr University Hospital, Clermont-Ferrand
  More Information

No publications provided

Responsible Party: Patrick Lacarin, CHU Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT01053845     History of Changes
Other Study ID Numbers: CHU-0066, 2009-A00155-52
Study First Received: January 19, 2010
Last Updated: January 18, 2011
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Clermont-Ferrand:
Neuropathic pain

Additional relevant MeSH terms:
Neuralgia
Stress, Psychological
Pain
Neurologic Manifestations
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Signs and Symptoms
Behavioral Symptoms

ClinicalTrials.gov processed this record on April 16, 2014